แขวงคลองตันเหนือ เขตวฒันา กรุงเทพมหานคร 10110 Revenue Revenue from Sales in Jan - Jun of 2017 was 576.4 MB increased by 247.3 MB or 75% y-o-y due to explain in each business segment summary as follows
-1- AIT (VP-SEC) 017E/2022 May 12, 2022 Subject: Management's Discussion and Analysis of Operating Results for Q1-2022 To: The President of the Stock Exchange of Thailand Summary of Operations Q1
Summary of operations and the factors that make a significant change Summary of Operations for the Year 2023 Operation Overview Annual Balance Change 2023 2022 2023 VS 2022 Million baht (MB) (MB) % Total
Thailand Ekachai Medical Care Public Company Limited (the “Company”) would like to clarify on the operating results for the yearly period at the end of 31st December 2018 as follows. Summary The Company
Thailand Ekachai Medical Care Public Company Limited (the “Company”) would like to clarify on the operating results for the yearly period at the end of 31st December 2019 as follows. Summary The Company
greater export sales portion. 3. In Q3 2017, the Company and its subsidiaries recorded the assets’ impairment loss and write- off of Solvay Biochemicals (Taixing) Limited (“SBT”) net amounting to 132 MB
: Price depending on the actual negotiated transaction prices between the buyer and seller (Referring to the book value as of December 31, 2016 at Baht 150.89 per share) Summary of financial statements
Exchange of Thailand Ekachai Medical Care Public Company Limited (the “Company”) would like to clarify on the operating results for the three-month period at the end of 31st March 2019 as follows. Summary
( 2 ) aspx ( 1 ) http://172.19.1.196:8983/solr/secweb/select?q=สินทรัพย์ดิจิทัล OR "Digital assets" OR "Digital properties"&wt=json&indent=true&facet=true&facet.field=key_filetype&facet.field
Dental Public Company Limited (LDC) would like to clarify the performance of the Company for the 6 months period ended June 30, 2018 which the details are as followed: Summary of the Company’s Performance